Mammoth Biosciences' Trevor Martin on using ultra-compact CRISPR systems to go after extra-hepatic indications in-vivo

blonca9
Jan 11, 2024
1 min read

Trevor Martin describes how Mammoth is working on the evolution of CRISPR to help make it more versatile for potential use in broad in-vivo applications.

Recent Posts

See All

After switching to a new GalNAc-LNP delivery vehicle a year ago, Verve Therapeutics today announced the initial safety and efficacy data from its VERVE-102 PCSK9 base editor

Jones Healthcare & Technology Innovation Conference: Pharvaris is developing oral bradykinin B2 receptor inhibitors for HEA - with a first pivotal scheduled to read in less than a year

Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June

Mammoth Biosciences' Trevor Martin on using ultra-compact CRISPR systems to go after extra-hepatic indications in-vivo

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight